It would be highly relevant to examine mutation and gene expression data from large cohorts of RR-DLBCL tumors obtained prior to platin-based treatment to determine whether XPA and ERCC6 can serve as prognostic biomarkers for the clinical outcomes of RR-DLBCL patients. The gene discussed is XPA; the disease is diffuse large B-cell lymphoma.